Schiffer E

Publications (4)16.07 Total impact

• Article: Proteomics in hypertension

  Carty DM, Schiffer E, Delles C
  Journal of Human Hypertension 08/2012; · 2.80 Impact Factor
• Source

  Available from: Petra Zürbig

  Article: Bile proteomic profiles differentiates cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis

  Lankisch TO, Metzger J, Negm AA, Voßkuhl K, Schiffer E, Siwy J, Weismüller TJ, Andrea S. Schneider AS, Thedieck K, Baumeister R, Zuerbig P, Weissinger EM, Manns MP, Mischak H, Wedemeyer J
  [show abstract] [hide abstract]
  ABSTRACT: Early detection of malignant biliary tract diseases, especially cholangiocarcinoma (CC) in patients with primary sclerosing cholangitis (PSC), is very difficult and often comes too late to give the patient a therapeutic benefit. We hypothesize that bile proteomic analysis distinguishes CC from nonmalignant lesions. We used capillary electrophoresis mass spectrometry (CE-MS) to identify disease-specific peptide patterns in patients with choledocholithiasis (n 5 16), PSC (n 5 18), and CC (n 5 16) in a training set. A model for differentiation of choledocholithiasis from PSC and CC (PSC/CC model) and another model distinguishing CC from PSC (CC model) were subsequently validated in independent cohorts (choledocholithiasis [n 5 14], PSC [n 5 18] and CC [n 5 25]). Peptides were characterized by sequencing. Application of the PSC/CC model in the independent test cohort resulted in correct exclusion of 12/14 bile samples from patients with choledocholithiasis and identification of 40/43 patients with PSC or CC (86% specificity, 93% sensitivity). The corresponding receiver operating characteristic (ROC) analysis revealed an area under the curve (AUC) of 0.93 (95% confidence interval [CI]: 0.82-0.98, P 5 0.0001). The CC model succeeded in an accurate detection of 14/18 bile samples from patients with PSC and 21/25 samples with CC (78% specificity, 84% sensitivity) in the independent cohort, resulting in an AUC value of 0.87 (95% CI: 0.73-0.95, P 5 0.0001) in ROC analysis. Eight out of 10 samples of patients with CC complicating PSC were identified. Conclusion: Bile proteomic analysis discriminates benign conditions from CC accurately. This method may become a diagnostic tool in future as it offers a new possibility to diagnose malignant bile duct disease and thus enables efficient therapy particularly in patients with PSC.
  Hepatology International 03/2011; 3(3-5):875-884. · 2.64 Impact Factor
• Article: Diagnostic marker pattern of sequenced urinary peptides for early and accurate detection of acute kidney injury

  Metzger J, Kirsch T, Schiffer E, Ulger P, Mentes E, Brand K, Weissinger EM, Haubitz M, Mischak H, Herget-Rosenthal S
  Kidney International 12/2010; 78(12):1252-62. · 6.61 Impact Factor
• Article: Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 subjects

  Delles C, Schiffer E, von zur Muhlen C, Peter K, Rossing P, Parving HH, Dymott JA, Neisius U, Zimmerli LU, Snell-Bergeon JK, Maahs DM, Schmieder RE, Mischak H, Dominiczak AF
  Journal of Hypertension 11/2010; 28(11):2316-22. · 4.02 Impact Factor